Molecular pathways: ROS1 fusion proteins in cancer

Clinical Cancer Research

Volumn 19, Issue 15, 2013, Pages 4040-4045

  Davies, Kurtis D ^a   Doebele, Robert C ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 26113; AT 13387; CD74 ANTIGEN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; PROTEIN TYROSINE PHOSPHATASE SHP 2; ROS1 FUSION PROTEIN; SODIUM PHOSPHATE COTRANSPORTER 2B; SYNDECAN 4; UNCLASSIFIED DRUG; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; ANGIOSARCOMA; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESEARCH; CARCINOGENICITY; COLORECTAL CANCER; FIBROBLAST; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE FUSION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEMANGIOENDOTHELIOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LIGAND BINDING; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; ONCOGENE; OVARY CANCER; PLASMA CELL GRANULOMA; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROS1 GENE; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE; TUMOR GROWTH; WILD TYPE; CELL PROLIFERATION; GENETICS; METABOLISM; MUTATION; NEOPLASMS; PATHOLOGY;

CELL PROLIFERATION; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES;

EID: 84881245421     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2851     Document Type: Article

References (47)

1. Matsushime H, Wang LH, Shibuya M. Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule. Mol Cell Biol 1986;6: 3000-4.
2. Birchmeier C, Birnbaum D, Waitches G, Fasano O, Wigler M. Characterization of an activated human ros gene. Mol Cell Biol 1986;6: 3109-16.
3. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-57.
4. Acquaviva J,WongR, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009;1795:37-52.
5. Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012;18: 4449-57.
6. El-Deeb IM, Yoo KH, Lee SH. ROS receptor tyrosine kinase: a new potential target for anticancer drugs. Med Res Rev 2010;31:794-818.
7. Sonnenberg-Riethmacher E, Walter B, Riethmacher D, Godecke S, Birchmeier C. The c-ros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis. Genes Dev 1996;10:1184-93.
8. Xiong Q, Chan JL, Zong CS, Wang LH. Two chimeric receptors of epidermal growth factor receptor and c-Ros that differ in their transmembrane domains have opposite effects on cell growth. Mol Cell Biol 1996;16:1509-18.
9. Zong CS, Zeng L, Jiang Y, Sadowski HB, Wang LH. Stat3 plays an important role in oncogenic Ros-And insulin-like growth factor I receptor-induced anchorage-independent growth. J Biol Chem 1998;273:28065-72.
10. Zeng L, Sachdev P, Yan L, Chan JL, Trenkle T, McClelland M, et al. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol 2000;20:9212-24.
11. Biskup C, Bohmer A, Pusch R, Kelbauskas L, Gorshokov A, Majoul I, et al. Visualization of SHP-1-target interaction. J Cell Sci 2004;117: 5165-78.
12. Nguyen KT, Zong CS, Uttamsingh S, Sachdev P, Bhanot M, Le MT, et al. The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in Ros-induced cell transformation. J Biol Chem 2002; 277:11107-15.
13. Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A 1987;84:9270-4.
14. Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 2003;37:58-71.
15. GuTL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS ONE 2011;6:e15640.
16. Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, et al. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS ONE 2011;6:e28250.
17. Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012;18:6599-608.
18. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
19. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18:378-81.
20. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-34.
21. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012;22:2109-19.
22. Lee J, Lee SE, Kang SY, Do IG, Lee S, Ha SY, et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 2013;119: 1627-35.
23. Weickhardt AJ, Nguyen TT, Paskulin DD, Le AT, Aisner D, Schulte N, et al. ALKandROSgene rearrangements detected in colorectal cancer (CRC) by fluorescence in situ hybridization (FISH). J Clin Oncol 31, 2013 (suppl; abstr 3545).
24. Lovly CM, Lipson D, Otto G, Brennan T, Sankar S, Stephens PJ, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. J Clin Oncol 31, 2013 (suppl; abstr 10513).
25. Giacomini CP, Sun S, Varma S, Shain AH, Giacomini MM, Balagtas J, et al. Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS Genet 2013;9:e1003464.
26. Charest A, Kheifets V, Park J, Lane K, McMahon K, Nutt CL, et al. Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc Natl Acad Sci U S A 2003;100: 916-21.
27. Jun HJ, Johnson H, Bronson RT, de Feraudy S, White F, Charest A. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res 2012;72:3764-74.
28. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, et al. Identifying and targeting ROS1gene fusions in non-small cell lung cancer. Clin Cancer Res 2012;18:4570-9.
29. Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/ phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res 2006;66:7473-81.
30. Arai Y, Totoki Y, Takahashi H, Nakamura H, Hama N, Kohno T, et al. Mouse model for ROS1-rearranged lung cancer. PLoS ONE 2013;8: e56010.
31. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68:3389-95.
32. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70.
33. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 2012;7:1086-90.
34. Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011;71: 4920-31.
35. Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol 2012;9: 268-77.
36. Chan JL, Lai M, Wang LH. Effect of dimerization on signal transduction and biological function of oncogenic Ros, insulin, and insulin-like growth factor I receptors. J Biol Chem 1997;272: 146-53.
37. Lee HJ, Seol HS, Kim JY, Chun SM, Suh YA, Park YS, et al. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. Ann Surg Oncol 2013;20:200-8.
38. Li C, Fang R, Sun Y, Han X, Li F, Gao B, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE 2011;6:e28204.
39. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
40. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011;17:2081-6.
41. Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013;37:554-62.
42. Ou SH, Camidge DR, Engelman J, Clark J, Tye L, Wilner K, et al. Clinical activity of crizotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangment. Ann Oncol 2012;23(Suppl 9):ix389.
43. Pao W, Chmielecki J. Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-74.
44. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive nonsmall-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9.
45. Anjum R, Vodala S, Zhang S, Moran L, Keats J, Squillace R, et al. The dual ALK/EGFR inhibitor AP26113 also potently inhibits activated and gatekeeper mutant forms of ROS1. EORTC Annual Meeting 2012: abstract 164.
46. Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013;3:430-43.
47. Hammerman PS, Janne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009;15:7502-9.